[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Apellis Pharmaceuticals insider James G. Chopas, listed as VP/Chief Accounting Officer, reported a sale of 548 shares of Apellis common stock on 09/02/2025 at a price of $28.077 per share. The filing states that the shares were sold to cover tax withholding on Restricted Stock Units released on August 29, 2025. After the transaction, Chopas beneficially owns 53,657 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025. No other derivative transactions or additional material information are reported.

Insights

Financial Analyst

TL;DR Routine insider sale to cover taxes; no change to overall ownership strategy indicated.

The reported sale of 548 shares at $28.077 appears to be a mechanical disposition to satisfy tax withholding on RSU vesting rather than a discretionary sale for diversification or liquidity. The remaining direct beneficial ownership of 53,657 shares is explicitly disclosed. From a quantitative perspective, the transaction size is small relative to the reported post-transaction holdings and there are no disclosed derivative positions or additional sales that would suggest a change in insider conviction.

Corporate Governance Expert

TL;DR Disclosure complies with Section 16 reporting; transaction documented as tax-withholding sale.

The Form 4 includes the required fields: reporting person identity, relationship to issuer (VP/Chief Accounting Officer), transaction date, code explanation, price, and post-transaction beneficial ownership. The explanation cites tax withholding for RSU release, which is a common, permissible reason for a sale under Rule 16b-3 practices. The filing was executed by an attorney-in-fact and includes a signature date, meeting standard procedural requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopas James George

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP/Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		548	D	$28.077	53,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on August 29, 2025.

	/s/ David Watson, attorney-in-fact for James Chopas	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did James G. Chopas report on the Form 4 for APLS?

He reported a sale of 548 shares of Apellis common stock on 09/02/2025 at $28.077 per share.

Why were the shares sold according to the filing?

The filing states the shares were sold to cover tax withholding on Restricted Stock Units that were released on August 29, 2025.

How many Apellis shares does Chopas beneficially own after the reported sale?

After the transaction he beneficially owns 53,657 shares, held directly.

What is James Chopas's role at Apellis as listed on the Form 4?

He is identified as a company Officer with the title VP/Chief Accounting Officer.

When was the Form 4 signed and by whom?

The Form 4 bears the signature of David Watson, attorney-in-fact for James Chopas dated 09/03/2025.